Morocco’s Cooper Pharma to build antibiotic manufacturing plant in Rwanda


Cooper Pharma, a Moroccan pharmaceutical maker, has inked a deal to build an antibiotic manufacturing facility in Rwanda.

The facility would be the first of its kind in the country, a state official told allAfrica. It is the second such plant construction deal by Cooper, which previously said it signed a deal in Abidjan, Ivory Coast.

The plant in Rwanda is slotted to be built on a nearly 33,000 square-foot plot of land in the Kigalir Special Economic Zone. The facility is expected to open in 2019 and will produce beta-lactam antibiotics, which are among the most commonly prescribed drugs, including Penicillins.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

The deal, which was designed to help meet local pharmaceutical needs, was announced during a three-day state visit by a Moroccan delegation led by King Mohamed VI.

"The market entry of Cooper Pharma… is in line with the long held wish by the government to have a pharmaceutical plant in Rwanda,” Serge Kamuhinda, the COO of the Rwanda Development Board, told allAfrica. “This will reduce our trade deficit and boost exports.”


Suggested Articles

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.

The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.